The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
n/a | 79 | 10 | 1 |
Growth
|
n/a | 53 | 85 | 39 |
Safety
|
n/a | 47 | 56 | 59 |
Sentiment
|
n/a | 16 | 71 | 49 |
|
n/a | 32 | 76 | 13 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
n/a | 7 | 75 | 89 |
Opinions Change
|
n/a | 50 | 50 | 50 |
Pro Holdings
|
n/a | 49 | 55 | 49 |
Market Pulse
|
n/a | 23 | 34 | 14 |
Sentiment
|
n/a | 16 | 71 | 49 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
n/a | 79 | 10 | 1 |
Growth
|
n/a | 53 | 85 | 39 |
|
n/a | 47 | 56 | 59 |
Combined
|
n/a | 70 | 56 | 81 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
n/a | 11 | 11 | 26 |
Price vs. Earnings (P/E)
|
n/a | 91 | 13 | 19 |
Price vs. Book (P/B)
|
n/a | 89 | 11 | 10 |
Dividend Yield
|
n/a | 1 | 1 | 1 |
Value
|
n/a | 79 | 10 | 1 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
n/a | 80 | 87 | 59 |
Profit Growth
|
n/a | 96 | 1 | 14 |
Capital Growth
|
n/a | 26 | 79 | 55 |
Stock Returns
|
n/a | 5 | 95 | 57 |
Growth
|
n/a | 53 | 85 | 39 |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
n/a | 14 | 45 | 100 |
Refinancing
|
n/a | 86 | 67 | 57 |
Liquidity
|
n/a | 26 | 35 | 22 |
|
n/a | 47 | 56 | 59 |
Discover high‑ranked alternatives to Marinus Pharmaceuticals and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.